More than 1,000 people each year could benefit from treatment with a combination of venetoclax and obinutuzumab, according to NICE.
List view / Grid view
Chronic lymphocytic leukaemia (CLL)
Filter the results
FDA approves IMBRUVICA® (ibrutinib) for treatment of chronic lymphocytic leukaemia and small lymphocytic lymphoma
IMBRUVICA (ibrutinib), in combination with rituximab, has been given approval in the US for the treatment of chronic lymphocytic leukaemia and small lymphocytic lymphoma.
KTE-X19, an investigational CAR T-cell therapy, has been granted marketing authorisation by the European Commission.
The European Commission has approved the drug for two indications: chronic lymphocytic leukaemia and Waldenström's macroglobulinemia.
NICE has issued a final appraisal determination recommending that venclyxto is made available to patients with chronic lymphocytic leukaemia...
The Scottish Medicines Consortium has published advice accepting three new medicines for routine use...
10 June 2016 | By
New data show promising results for venetoclax in patients with chronic lymphocytic leukaemia who have relapsed or become refractory (R/R) to treatment...
1 June 2016 | By Victoria White, Digital Content Producer
The National Institute for Health and Care Excellence (NICE) has asked Janssen to set out a case for including its chronic lymphocytic leukaemia (CLL) drug ibrutinib (Imbruvica) in the Cancer Drugs Fund (CDF).
The EC has approved the subcutaneous formulation of MabThera for people with previously untreated and relapsed/refractory chronic lymphocytic leukaemia...
31 May 2016 | By Victoria White, Digital Content Producer
The European Commission (EC) has approved Imbruvica (ibrutinib) for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).
12 April 2016 | By Victoria White, Digital Content Producer
Venclexta is the first FDA-approved treatment that targets the BCL-2 protein, which supports cancer cell growth and is overexpressed in many CLL patients...
AstraZeneca and Acerta Pharma have announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) adopted three positive opinions recommending acalabrutinib (ACP-196) for designation as an orphan medicinal product.
20 January 2016 | By Victoria White
Venetoclax is an investigational small molecule designed to selectively bind and inhibit the BCL-2 protein, which plays an important role in a process called apoptosis...